VentiRx extends series A by $25 million
This article was originally published in Scrip
Executive Summary
VentiRx Pharmaceuticals, a private US firm focused on the development of novel toll-like receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, has raised $25 million in an extension of its series A round.